卡培他滨联合奥沙利铂术前新辅助化疗治疗中晚期胃癌的疗效探讨

Efficacy of Capecitabine Combined with Oxaliplatin Preoperative Neoadjuvant Chemotherapy in the Treatment of Advanced Gastric Cancer

目的分析探讨卡培他滨联合奥沙利铂术前新辅助化疗治疗中晚期胃癌的临床疗效。方法选取该院于2014年1月—2015年1月收治的72例中晚期胃癌患者,随机分为2组,对照组采取顺铂联合氟尿嘧啶化疗,观察组采取卡培他滨联合奥沙利铂术前新辅助化疗,对比评价两组临床治疗。结果在治疗总有效率方面,观察组为66.67%,明显高于对照组44.44%。在1年生存率、2年生存率方面,观察组均明显高于对照组(P<0.05);此外,观察组复发率为11.11%,明显低于对照组的30.56%,两组数据差异有统计学意义(P<0.05)。此外,两组不良反应发生差异无统计学意义(P>0.05)。结论针对中晚期胃癌患者,采取卡培他滨联合奥沙利铂术前新辅助化疗的疗效显著,值得采纳及应用。

Objective This paper tries to investigate the clinical efficacy of capecitabine combined with oxaliplatin preoperative neoadjuvant chemotherapy in the treatment of advanced gastric cancer.Methods 72 cases of advanced gastric cancer patients in this hospital from January 2014 to January 2015 were randomly divided into two groups,the control group took cisplatin and fluorouracil chemotherapy,the observation group took capecitabine neoadjuvant chemotherapy in combination with oxaliplatin in preoperative evaluation,the clinical treatment of two groups were compared.Results In the total effective rate,the observation group was 66.67%,significantly higher than 44.44%of the control group.In the one year survival rate and two years survival rate,the observation group was significantly higher than the control group(P<0.05);in addition,the recurrence rate of the observation group was 11.11%,significantly lower than the control group of 30.56%,two groups had statistically significant difference(P<0.05)data.In addition,there was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion For patients with advanced gastric cancer,capecitabine combined with oxaliplatin preoperative neoadjuvant chemotherapy is effective,which is worthy of adoption and application.